JPWO2022236136A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022236136A5 JPWO2022236136A5 JP2023568528A JP2023568528A JPWO2022236136A5 JP WO2022236136 A5 JPWO2022236136 A5 JP WO2022236136A5 JP 2023568528 A JP2023568528 A JP 2023568528A JP 2023568528 A JP2023568528 A JP 2023568528A JP WO2022236136 A5 JPWO2022236136 A5 JP WO2022236136A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- group
- compound
- triazolyl
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185736P | 2021-05-07 | 2021-05-07 | |
| US63/185,736 | 2021-05-07 | ||
| US202163248705P | 2021-09-27 | 2021-09-27 | |
| US63/248,705 | 2021-09-27 | ||
| US202263321187P | 2022-03-18 | 2022-03-18 | |
| US63/321,187 | 2022-03-18 | ||
| PCT/US2022/028193 WO2022236136A1 (en) | 2021-05-07 | 2022-05-06 | Exatecan derivatives and antibody-drug conjugates thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024518438A JP2024518438A (ja) | 2024-05-01 |
| JP2024518438A5 JP2024518438A5 (https=) | 2025-05-14 |
| JPWO2022236136A5 true JPWO2022236136A5 (https=) | 2025-05-14 |
Family
ID=81851425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568528A Pending JP2024518438A (ja) | 2021-05-07 | 2022-05-06 | エキサテカン誘導体およびその抗体薬物複合体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20250101032A1 (https=) |
| EP (1) | EP4334322A1 (https=) |
| JP (1) | JP2024518438A (https=) |
| KR (1) | KR20240036506A (https=) |
| AU (1) | AU2022269073A1 (https=) |
| BR (1) | BR112023023276A2 (https=) |
| CA (1) | CA3219236A1 (https=) |
| CL (1) | CL2023003304A1 (https=) |
| CO (1) | CO2023016939A2 (https=) |
| GE (1) | GEAP202416409A (https=) |
| IL (1) | IL308246A (https=) |
| MX (1) | MX2023013118A (https=) |
| PE (1) | PE20241299A1 (https=) |
| TW (1) | TW202309042A (https=) |
| WO (1) | WO2022236136A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240038138A (ko) | 2020-07-13 | 2024-03-22 | 리제너론 파마슈티칼스 인코포레이티드 | 단백질에서 글루타민 잔기에 접합된 캄토테신 유사체 및 그의 용도 |
| MX2023003778A (es) | 2020-09-30 | 2023-04-26 | Duality Biologics Suzhou Co Ltd | Compuesto antitumoral, metodo de preparacion y uso del mismo. |
| CN114805377A (zh) * | 2021-01-29 | 2022-07-29 | 明慧医药（杭州）有限公司 | 适用于抗体-药物偶联物的毒素分子 |
| AU2022375634A1 (en) | 2021-10-25 | 2024-06-06 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| EP4434548A1 (en) | 2021-11-15 | 2024-09-25 | Systimmune, Inc. | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof |
| US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
| CA3241734A1 (en) * | 2022-01-12 | 2023-07-20 | Amy Han | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use |
| EP4489790A1 (en) * | 2022-03-10 | 2025-01-15 | Vivasor, Inc. | Antibody-drug conjugates and uses thereof |
| CN118696048A (zh) * | 2022-05-09 | 2024-09-24 | 同宜医药（苏州）有限公司 | 一种喜树碱衍生物，基于其的抗体-药物偶联物和药物组合物，及其应用 |
| KR20250075560A (ko) | 2022-07-15 | 2025-05-28 | 진콴텀 헬스케어 (쑤저우) 씨오., 엘티디. | 항-trop2 항체 및 이의 접합체 |
| KR20250049293A (ko) * | 2022-07-27 | 2025-04-11 | 밍훼이 파마슈티컬 (항저우) 리미티드 | 항체-약물 접합체 및 이의 용도 |
| CN117510515A (zh) * | 2022-07-28 | 2024-02-06 | 明慧医药（杭州）有限公司 | 适用于抗体-药物偶联物的毒素分子 |
| CN117024438A (zh) * | 2022-07-29 | 2023-11-10 | 杭州爱科瑞思生物医药有限公司 | 依沙替康衍生物及其应用 |
| JP2025511436A (ja) * | 2022-09-02 | 2025-04-16 | メルク・シャープ・アンド・ドーム・エルエルシー | エキサテカン由来トポイソメラーゼ－１阻害薬医薬組成物及びその使用 |
| EP4594327A1 (en) | 2022-09-30 | 2025-08-06 | BeiGene Switzerland GmbH | Ligand-drug conjugate of exatecan analogue, and medical use thereof |
| PE20252282A1 (es) * | 2022-10-09 | 2025-09-18 | Lanova Medicines Ltd | Compuestos, composiciones y metodos |
| IL320634A (en) * | 2022-11-04 | 2025-07-01 | Alx Oncology Inc | EXATECAN derivatives and antibody-drug conjugates |
| CN119855820A (zh) * | 2022-12-16 | 2025-04-18 | 上海齐鲁制药研究中心有限公司 | 喜树碱类化合物及其制备方法和用途 |
| WO2024130161A2 (en) | 2022-12-16 | 2024-06-20 | Bionecure Therapeutics Inc | Novel camptothecin derivatives and conjugates thereof |
| IL321193A (en) * | 2022-12-28 | 2025-07-01 | Adcendo Aps | Antibody-drug conjugates targeting UPARAP including extacan derivatives |
| CN119630672B (zh) * | 2023-02-23 | 2026-01-30 | 一线医药（杭州）有限公司 | 喜树碱衍生物及其偶联物以及其制备方法和医药用途 |
| CN116063311B (zh) * | 2023-03-01 | 2025-09-26 | 金麦安博生物制药(苏州)有限公司 | 一种依喜替康衍生物及其制备方法 |
| CN120916790A (zh) * | 2023-03-27 | 2025-11-07 | 台湾浩鼎生技股份有限公司 | Trop2耦合生物分子、医药组合物及方法 |
| TW202438069A (zh) * | 2023-03-30 | 2024-10-01 | 大陸商上海齊魯製藥研究中心有限公司 | 依喜替康衍生物及其抗體藥物偶聯物 |
| EP4687996A1 (en) * | 2023-04-05 | 2026-02-11 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
| EP4687997A2 (en) * | 2023-04-05 | 2026-02-11 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
| EP4687995A1 (en) * | 2023-04-05 | 2026-02-11 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
| US20240398794A1 (en) | 2023-04-07 | 2024-12-05 | Terns Pharmaceuticals, Inc. | COMBINATIONS OF GLP-1R AND THRß AGONISTS AND METHODS OF USE THEREOF |
| WO2024227432A1 (zh) * | 2023-04-30 | 2024-11-07 | 泰诚思(上海)生物医药有限公司 | 喜树碱衍生物、其制备方法及用途、抗体药物偶联物及其应用 |
| CN119080792A (zh) * | 2023-09-15 | 2024-12-06 | 杭州爱科瑞思生物医药有限公司 | 依沙替康羟胺衍生物及其应用 |
| CN120641100A (zh) * | 2023-09-22 | 2025-09-12 | 台湾浩鼎生技股份有限公司 | 用于抗体耦合的改良型连接符-负载物、医药组合物、及其应用 |
| CN117417347A (zh) * | 2023-09-28 | 2024-01-19 | 杭州爱科瑞思生物医药有限公司 | 卤素取代的依沙替康的酰胺衍生物及其制备方法和应用 |
| CN117645608A (zh) * | 2023-11-30 | 2024-03-05 | 昆山新蕴达生物科技有限公司 | 抗体药物偶联物及其应用 |
| WO2025141153A1 (en) * | 2023-12-29 | 2025-07-03 | Oncomatryx Biopharma, S.L. | Endo180 targeted antibody-drug conjugates |
| CN117986269A (zh) * | 2024-01-18 | 2024-05-07 | 苏州提领生物制药有限公司 | 喜树碱衍生物及其制备方法和应用 |
| WO2025167722A1 (zh) * | 2024-02-06 | 2025-08-14 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物及其制备方法和应用 |
| WO2025207828A1 (en) * | 2024-03-26 | 2025-10-02 | Fulgent Pharma Llc | Nanocomposition comprising modified exatecan and use thereof |
| WO2025233501A1 (en) * | 2024-05-10 | 2025-11-13 | Astrazeneca Ab | Conjugates comprising a topoisomerase i inhibitor |
| WO2025247302A1 (zh) * | 2024-05-31 | 2025-12-04 | 杭州中美华东制药有限公司 | 一种喜树碱类化合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3466976T1 (sl) * | 2014-01-31 | 2021-12-31 | Daiichi Sankyo Company, Limited | Anti-her2 konjugat protitelesa-zdravila |
| JP6612738B2 (ja) * | 2014-04-10 | 2019-11-27 | 第一三共株式会社 | 抗ｈｅｒ２抗体−薬物コンジュゲート |
| WO2020063676A1 (zh) * | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
| CN111620927B (zh) * | 2019-05-20 | 2022-11-11 | 烟台迈百瑞国际生物医药股份有限公司 | 一种抗体药物偶联物中间体的一锅法制备工艺 |
| CN111689980A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种喜树碱药物及其抗体偶联物 |
| CN112125915A (zh) * | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
| MX2023003778A (es) | 2020-09-30 | 2023-04-26 | Duality Biologics Suzhou Co Ltd | Compuesto antitumoral, metodo de preparacion y uso del mismo. |
-
2022
- 2022-05-06 BR BR112023023276A patent/BR112023023276A2/pt unknown
- 2022-05-06 TW TW111117169A patent/TW202309042A/zh unknown
- 2022-05-06 KR KR1020237042383A patent/KR20240036506A/ko active Pending
- 2022-05-06 AU AU2022269073A patent/AU2022269073A1/en active Pending
- 2022-05-06 GE GEAP202416409A patent/GEAP202416409A/en unknown
- 2022-05-06 CA CA3219236A patent/CA3219236A1/en active Pending
- 2022-05-06 EP EP22726339.9A patent/EP4334322A1/en active Pending
- 2022-05-06 WO PCT/US2022/028193 patent/WO2022236136A1/en not_active Ceased
- 2022-05-06 US US18/559,185 patent/US20250101032A1/en active Pending
- 2022-05-06 MX MX2023013118A patent/MX2023013118A/es unknown
- 2022-05-06 JP JP2023568528A patent/JP2024518438A/ja active Pending
- 2022-05-06 PE PE2023003021A patent/PE20241299A1/es unknown
- 2022-05-06 IL IL308246A patent/IL308246A/en unknown
-
2023
- 2023-11-07 CL CL2023003304A patent/CL2023003304A1/es unknown
- 2023-12-05 CO CONC2023/0016939A patent/CO2023016939A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2022236136A5 (https=) | ||
| JP2020007311A5 (https=) | ||
| JP2022541467A (ja) | オーロラキナーゼ阻害剤およびその使用 | |
| JP2025024130A5 (https=) | ||
| RU2011121655A (ru) | Производные пиридина, бициклические производные пиридина и родственные аналоги в качестве модуляторов сиртуина | |
| JP2019530724A5 (https=) | ||
| CA2736039C (en) | Novel prostaglandin i2 derivative | |
| RU2006122209A (ru) | Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы | |
| CA2486537A1 (en) | 4-(substituted cycloalkylmethyl)imidazole-2-thiones, 4-(substituted cycloalkenylmethyl)imidazole-2-thiones, 4-(substituted cycloalkylmethyl)imidazol-2-ones and 4-(substituted cycloalkenylmethyl)imidazol-2-ones and related compounds | |
| JPWO2020123827A5 (https=) | ||
| ES2493627T3 (es) | Derivados de N-fenil-2-pirimidina-amina y proceso para la preparación de los mismos | |
| JP2019531346A5 (https=) | ||
| JPWO2020023560A5 (https=) | ||
| JP2002529465A5 (https=) | ||
| JP2014520108A5 (https=) | ||
| CA2527315A1 (en) | Imidazole derivatives as glutamate receptor antagonists | |
| JPWO2019213445A5 (https=) | ||
| JP2021534254A5 (ja) | 心臓弁疾患を治療するための医薬組成物 | |
| JPWO2023016529A5 (https=) | ||
| JP2008530045A5 (https=) | ||
| JPWO2021262810A5 (https=) | ||
| JPWO2021262812A5 (https=) | ||
| CA2246727C (en) | Novel substituted n-methyl-n-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases | |
| JPWO2022111621A5 (https=) | ||
| RU2023132109A (ru) | Производные экзатекана и их коньюгаты антитело-лекарственное средство |